한글목차

주요 7개 시장(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 심부전(HF) 치료제 매출은 2022년 약 135억 달러로 추정됩니다. 심부전(HF) 시장 규모는 2032년까지 연평균 9.6%의 높은 성장률을 보이며 예측 기간 말에 337억 달러의 매출에 도달할 것으로 예상됩니다.

예측 기간 동안 HF 시장 성장의 주요 촉진요인

• Bayer의 케렌디아(피네레논)의 적응증 확대가 기대됨
• 여러 가지 경구 및 주사제 출시
• 전 세계 만성 심부전 유병률 증가

예측 기간 동안 HF 시장의 성장을 저해하는 주요 장벽

• 최근 HF 치료제의 높은 가격
• 심장 전문의 및 기타 의사들이 새로운 HF 치료제를 채택하거나 처방하는 데 소극적임
• 고가 브랜드 치료제의 시장 침투가 어려워지고 있는 상황에서 HF 치료제의 제네릭 의약품의 보급이 확산되고 있음

이 보고서는 심부전(HF)의 7대 주요 시장을 조사하여 심부전 개요, 심부전 치료제 시장 수익 및 예측, 파이프라인 분석, 현재 및 미래 경쟁 분석 등을 제공합니다.

목차

제1장 심부전(HF) : 주요 요약 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• HF 시장은 2022-2032년에 강력한 성장을 나타낸다
• CV 의약품 적응 확대가 시장 성장을 촉진
• HF 시장에서는 확립된 치료법이 있음에도 불구하고 미충족 수요가 남아 있다
• HF 시장은 주사제가 주류가 된다
• 의사의 생각

제2장 소개 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 촉매
• 관련 보고서

제3장 질환 개요

• 병인과 병태생리학
  • 병인
  • 병태생리학
  • 관심을 모으고 있는 바이오마커/타겟
• 분류 또는 병기분류 시스템
• 예후

제4장 역학

• 질환 배경
• 위험인자와 합병증
• 세계의 과거 동향
• 예측 방법
• HF 역학 예측(2022-2032년)
  • HF 발증자수
  • HF 발증자수 : 연령별
  • HF 발증자수 : 성별
  • HF 발증자수 : 박출률별
  • 급성 HF에서의 입원
  • 증상에 기반한 급성 HF 입원
  • 급성 HF 입원 기간
  • 급성 HF 후 퇴원 후 30일 이내 재입원
  • HF 유병자수
  • HF 유병자수 : 연령별
  • HF 유병자수 : 성별
  • HF 유병자수 : 박출률별
  • HF 유병자수 : New York Heart Association 클래스별
  • 좌심실 박출률이 유지된 HF(좌심실 박출률 50% 이하) 유병자수 : New York Heart Association 클래스별
  • 좌심실 박출률이 경미하게 저하된 HF(좌심실 박출률 40-49%) 유병자수 : New York Heart Association 클래스별
  • 좌심실 박출률이 저하된 HF(좌심실 박출률 40% 미만) 유병자수 : New York Heart Association 클래스별
  • HF 유병자수 : American College of Cardiology Foundation/American Heart Association 스테이지별
• 논의
  • 역학 예측 인사이트
  • COVID-19의 영향
  • 분석의 한계
  • 분석의 강점

제5장 질병 관리 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 진단과 치료 개요
• 질병 관리에 관한 KOL의 인사이트

제6장 현재 치료 옵션 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요

제7장 미충족 수요와 기회 평가 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요
• 박출률이 유지된 HF 환자에 대한 치료법의 부족
• 급성 HF 치료법의 부족
• HF 치료 컴플라이언스와 최적인 관리
• HF 발증 리스크가 있는 환자에 대한 예방 요법

제8장 R&D 전략 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요
  • 다른 적응증으로 승인된 치료법 적응 확대
  • 제품 파이프라인을 확대하기 위한 인수합병
• 임상시험 설계
  • HF 임상 엔드포인트
  • 포함 기준과 제외 기준

제9장 파이프라인 평가 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요
• 임상 개발중인 유망한 의약품

제10장 파이프라인 평가 분석 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요
• 경쟁 평가

제11장 현재 기업과 향후 기업 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 개요
• 거래 동향

제12장 시장 전망 - 2024년 10월 업데이트, 2024년 10월 24일까지 사건에 근거

• 세계 시장
  • 예측
  • 성장 촉진요인과 장벽 - 세계의 문제
• 미국
  • 예측
  • 주요 사건
  • 성장 촉진요인과 장벽
• 유럽 5개국
  • 예측
  • 주요 사건
  • 성장 촉진요인과 장벽
• 일본
  • 예측
  • 주요 사건
  • 성장 촉진요인과 장벽

제13장 부록

영문목차

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the heart failure market through 2032.

GlobalData estimates sales of HF therapeutics to be approximately $13.5 billion across the 7MM in 2022. By 2032, GlobalData expects the HF market to grow at a strong compound annual growth rate (CAGR) of 9.6%, reaching sales of $33.7 billion by the end of the forecast period.

Major drivers of HF market growth over the forecast period are the -

• Anticipated expanded indication for Bayer's Kerendia (finerenone)
• Launch of several oral and injectable agents
• Increase in the global prevalence of chronic HF

Major barriers that will restrict the growth of the HF market during the forecast period are the -

• High price of recently developed HF therapies
• General reluctance of cardiologists and other physicians to adopt and prescribe new HF therapies
• Widespread use of generic HF drugs, making it difficult for high-priced branded therapies to penetrate the market

Scope

• Overview of heart failure, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized heart failure therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the heart failure therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for heart failure treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global heart failure therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM heart failure therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM heart failure therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Heart Failure: Executive Summary - Updated October 2024, Based on Events up to October 24, 2024

• 1.1 The HF market will exhibit strong growth between 2022 and 2032
• 1.2 Label expansions of CV drugs will fuel market growth
• 1.3 Unmet needs remain in the HF market despite the availability of well-established therapies
• 1.4 Injectable agents will dominate the HF market
• 1.5 What do physicians think?

2 Introduction - Updated October 2024, Based on Events up to October 24, 2024

• 2.1 Catalyst
• 2.2 Related reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 Biomarkers/targets of interest
• 3.2 Classification or staging systems
• 3.3 Prognosis

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
  • 4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction
  • 4.4.5 Forecast assumptions and methods: hospitalizations for acute HF
  • 4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
  • 4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations
  • 4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
  • 4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
  • 4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction
  • 4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes
  • 4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction >=50%) by New York Heart Association class
  • 4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40-49%) by New York Heart Association class
  • 4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction <40%) by New York Heart Association class
  • 4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
• 4.5 Epidemiological forecast for HF (2022-32)
  • 4.5.1 Diagnosed incident cases of HF
  • 4.5.2 Age-specific diagnosed incident cases of HF
  • 4.5.3 Sex-specific diagnosed incident cases of HF
  • 4.5.4 Diagnosed incident cases of HF by ejection fraction
  • 4.5.5 Hospitalizations for acute HF
  • 4.5.6 Acute HF hospitalizations based on presentation
  • 4.5.7 Hospital length of stay for acute HF
  • 4.5.8 Re-admissions within 30 days post-discharge after acute HF
  • 4.5.9 Diagnosed prevalent cases of HF
  • 4.5.10 Age-specific diagnosed prevalent cases of HF
  • 4.5.11 Sex-specific diagnosed prevalent cases of HF
  • 4.5.12 Diagnosed prevalent cases of HF by ejection fraction
  • 4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class
  • 4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction >=50%) by New York Heart Association class
  • 4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40-49%) by New York Heart Association class
  • 4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction <40%) by New York Heart Association class
  • 4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management - Updated October 2024, Based on Events up to October 24, 2024

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Current Treatment Options - Updated October 2024, Based on Events up to October 24, 2024

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated October 2024, Based on Events up to October 24, 2024

• 7.1 Overview
• 7.2 Lack of therapies for HF with preserved ejection fraction patients
• 7.3 Lack of therapies for acute HF
• 7.4 Compliance and optimal management of HF treatments
• 7.5 Preventative therapies for patients at risk of developing HF

8 R&D Strategies - Updated October 2024, Based on Events up to October 24, 2024

• 8.1 Overview
  • 8.1.1 Label expansion for therapies approved for other indications
  • 8.1.2 Mergers and acquisitions to expand the product pipeline
• 8.2 Clinical trials design
  • 8.2.1 Clinical endpoints for HF
  • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment - Updated October 2024, Based on Events up to October 24, 2024

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis - Updated October 2024, Based on Events up to October 24, 2024

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players - Updated October 2024, Based on Events up to October 24, 2024

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook - Updated October 2024, Based on Events up to October 24, 2024

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Vice President of Disease Intelligence and Epidemiology
  • 13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• Contact Us